Advertisement
GMED vs MDT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Buy and MDT is a Buy.
GMED in upward trend: price rose above 50-day moving average on October 20, 2026
GMED moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on GMED as a result. In 59 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for GMED just turned positive on September 25, 2026. Looking at past instances where GMED's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 198 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.215) is normal, around the industry mean (2.923). P/E Ratio (19.819) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
MDT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for MDT moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 51 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 170 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 11 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
MDT broke above its upper Bollinger Band on October 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MDT entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.369) is normal, around the industry mean (2.923). P/E Ratio (22.746) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.052). Dividend Yield (0.031) settles around the average of (0.009) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
GMED | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 65 | 68 | |
PRICE GROWTH RATING 1..100 | 46 | 27 | |
P/E GROWTH RATING 1..100 | 61 | 56 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (39) in the Medical Specialties industry is somewhat better than the same rating for GMED (79). This means that MDT’s stock grew somewhat faster than GMED’s over the last 12 months.
MDT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as GMED (100). This means that MDT’s stock grew similarly to GMED’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is in the same range as MDT (68). This means that GMED’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (27) in the Medical Specialties industry is in the same range as GMED (46). This means that MDT’s stock grew similarly to GMED’s over the last 12 months.
MDT's P/E Growth Rating (56) in the Medical Specialties industry is in the same range as GMED (61). This means that MDT’s stock grew similarly to GMED’s over the last 12 months.
| GMED | MDT | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 42% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 48% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 65% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 50% |
| Advances ODDS (%) | 10 days ago 64% | 8 days ago 54% |
| Declines ODDS (%) | 4 days ago 58% | 4 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 40% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 46% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s).
- GMED’s FA Score: 0 green, 5 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s).
- GMED’s TA Score: 4 bullish, 4 bearish.
- MDT’s TA Score: 6 bullish, 5 bearish.
Price Growth
GMED (@Medical/Nursing Services) experienced а +3.11% price change this week, while MDT (@Medical/Nursing Services) price change was -1.27% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
GMED is expected to report earnings on Nov 05, 2026.
MDT is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
GMED and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with TMCI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then TMCI could also see price increases.
| Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
|---|---|---|---|---|
| GMED | 100% | -0.35% | ||
| TMCI - GMED | 46% Loosely correlated | +1.72% | ||
| TNDM - GMED | 46% Loosely correlated | -1.03% | ||
| SYK - GMED | 44% Loosely correlated | -2.23% | ||
| MDT - GMED | 44% Loosely correlated | -1.69% | ||
| STE - GMED | 44% Loosely correlated | -1.64% | ||
More | ||||
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.